Anne Bridgen

Reverse Genetics of RNA Viruses (eBook, ePUB)

Applications and Perspectives

• Format: ePub

Produktbeschreibung

Reverse genetics, the genetic manipulation of RNA viruses to create a wild-type or modified virus, has led to important advances in our understanding of viral gene function and interaction with host cells. Since many severe viral human and animal pathogens are RNA viruses, including those responsible for polio, measles, rotaviral diarrhoea and influenza infections, it is also an extremely powerful technique with important potential application for the prevention and control of a range of human and animal viral diseases. Reverse Genetics of RNA Viruses provides a comprehensive account of the very latest developments in reverse genetics of RNA viruses through a wide range of applications within each of the core virus groups including; positive sense, negative sense and double stranded RNA viruses. Written by a team of international experts in the field, it provides a unique insight into how the field has developed, what problems are being addressed now and where applications may lead in the future. It will prove invaluable to bioscience, medical and veterinary students, those starting research in this area as well as other researchers and teachers needing to update their knowledge of this fast-moving field. * An authoritative, comprehensive overview of reverse genetics in RNA Viruses. * Includes numerous examples of cutting- edge applications of reverse genetics within each of the RNA viral groups. * Written by a team of international experts, including some of the leading researchers in the field.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: John Wiley & Sons
• Seitenzahl: 412
• Erscheinungstermin: 8. Oktober 2012
• Englisch
• ISBN-13: 9781118405345
• Artikelnr.: 37338610

Autorenporträt

Dr Anne Bridgen, previously of The University of Ulster is a molecular virologist with extensive research and teaching experience. She was the first scientist to recover infectious virus particles from DNA clones of a segmented RNA virus. Dr Bridgen knows the field and its main players well and has both the knowledge and experience to bring individual expert contributions together around the common theme of reverse genetics. She is currently providing consultancy for a BBSRC grant based at IAH Pirbright.

Inhaltsangabe

List of contributors xi Acknowledgements xiii 1 Introduction 1 Anne Bridgen
1.1 Background 1 1.2 Reverse genetics for different classes of genome 2 1.3
Methodology 5 1.4 Difficulties in establishing a reverse genetics system 11
1.5 Recent developments 13 1.6 Are there any boundaries for conducting
reverse genetics? 13 References 15 Part I Positive sense RNA viruses 25 2
Coronavirus reverse genetics 27 Maria Armesto, Kirsten Bentley, Erica
Bickerton, Sarah Keep and Paul Britton 2.1 The Coronavirinae 27 2.2
Infectious bronchitis 28 2.3 Coronavirus genome organisation 29 2.4 The
coronavirus replication cycle 30 2.5 Development of reverse genetics system
for coronaviruses including IBV 33 2.6 Reverse genetics system for IBV 37
2.7 Reverse genetics systems for the modification of coronavirus genomes 40
2.8 Using coronavirus reverse genetics systems for gene delivery 49
Acknowledgements 51 References 51 3 Reverse genetic tools to study
hepatitis C virus 64 Alexander Ploss 3.1 Introduction: hepatitis C 64 3.2
Hepatitis C virus 65 3.3 Construction of infectious clones for hepatitis C
virus 68 3.4 Study of HCV RNA replication in cell culture systems 68 3.5
Use of HCV replicons to study viral replication 70 3.6 Utility of replicons
for drug screening 71 3.7 Development of the infectious cell culture
systems for HCV 71 3.8 Construction of intergenotypic viral chimeras 72 3.9
Non-JFH1 derived genomes 74 3.10 Cell lines that support HCV replication 74
3.11 Study of HCV in physiologically more relevant cell culture systems 75
3.12 Animal models for HCV infection 76 3.13 Reverse genetics of clinically
relevant HCV genotypes in vivo 77 3.14 Conclusion 78 Acknowledgments 78
References 78 4 Calicivirus reverse genetics 91 Ian Goodfellow 4.1
Introduction 91 4.2 Feline calicivirus 93 4.3 Murine norovirus 97 4.4
Porcine enteric calicivirus 103 4.5 Rabbit haemorrhagic disease virus 104
4.6 Human norovirus 104 4.7 Conclusion 106 Acknowledgements 107 References
107 Part II Negative sense RNA viruses 113 5 Reverse genetics of
rhabdoviruses 115 Alexander Ghanem and Karl-Klaus Conzelmann 5.1
Introduction: the Rhabdoviridae family 115 5.2 Rhabdovirus reverse genetics
121 5.3 Applications and examples 132 5.4 Conclusion 137 Acknowledgements
137 References 137 6 Modification of measles virus and application to
pathogenesis studies 150 Linda J. Rennick and W. Paul Duprex 6.1
Introduction 150 6.2 Measles: the disease 150 6.3 Measles: the infectious
agent 151 6.4 RNA synthesis: a tail of two processes 154 6.5 Transcription:
starting, stopping, dropping off or starting again 154 6.6 From
transcription to replication: the elusive switch 155 6.7 Getting in and
getting out 157 6.8 Measles virus: reverse genetics 158 6.9 Future
perspectives 181 Acknowledgements 182 References 182 7 Bunyavirus reverse
genetics and applications to studying interactions with host cells 200
Richard M. Elliott 7.1 Introduction: the family Bunyaviridae 200 7.2
Bunyavirus replication 201 7.3 History of bunyavirus reverse genetics 203
7.4 Minigenome systems for bunyaviruses 205 7.5 Virus-like particle
production 207 7.6 Rescue systems for bunyaviruses 208 7.7 Application of
reverse genetics to study bunyavirus replication 208 7.8 Outlook 215
References 216 8 Using reverse genetics to improve influenza vaccines 224
Ruth A. Elderfield, Lorian C.S. Hartgroves and Wendy S. Barclay 8.1
Introduction 224 8.2 Influenza vaccines 227 8.3 The use of reverse genetics
to generate recombinant influenza A, B and C viruses 229 8.4 Using reverse
genetics technology for generation of pandemic virus vaccine 232 8.5 Other
strategies for generating live attenuated vaccines based on viruses
engineered by reverse genetics 235 8.6 Strategies to improve the safety or
yield of influenza vaccines 238 8.7 Improvements to the PR8 high growth
strain 239 8.8 Improving the immunogenicity by engineering recombinant
viruses that express cytokine genes 240 8.9 Novel species-specific
attenuation that takes advantage of microRNAs 240 8.10 Conclusion 241
References 241 Part III Double-stranded RNA viruses 251 9 Bluetongue virus
reverse genetics 253 Mark Boyce 9.1 Introduction to Bluetongue virus 253
9.2 Bluetongue virus replication 254 9.3 Reverse genetics 260 9.4 Uses of
reverse genetics in orbivirus research 271 9.5 Future perspectives 278 10
Genetic modification in mammalian orthoreoviruses 289 Sanne K. van den
Hengel, Iris J.C. Dautzenberg, Diana J.M. van den Wollenberg, Peter A.E.
Sillevis Smitt and Rob C. Hoeben 10.1 Introduction 289 10.2
Forward-genetics in orthoreoviruses 296 10.3 Reovirus/cell interactions 297
10.4 Reverse-genetics in orthoreoviruses 301 10.5 Reovirus as an oncolytic
agent 306 10.6 Conclusion 308 References 309 Part IV Recent and future
developments 319 11 Reverse genetics and quasispecies 321 Antonio V.
Border¿?a and Marco Vignuzzi 11.1 Definition of quasispecies and evidence
321 11.2 Reverse genetics and RNA virus population heterogeneity: consensus
is always a compromise 328 11.3 Examples of the use of the theory to
disable or manipulate the quasispecies under controlled environments 333
11.4 Future prospects of virus population genetics and reverse genetics 339
11.5 Conclusion 341 References 342 12 Summary and perspectives 350 Anne
Bridgen 12.1 Introduction 350 12.2 Analysis of the role of specific
non-coding sequence motifs involved in replication, transcription,
polyadenylation and packaging 351 12.3 Analysis of the roles of viral
proteins 352 12.4 Analysis of virus-host interactions at a global level 353
12.5 Understanding the basis of pathogenicity 354 12.6 Real-time virus
imaging in vitro and in vivo 355 12.7 Structure-function analysis of
viruses and viral domains 356 12.8 Vaccine generation 357 12.9 Drug
development 359 12.10 Gene delivery and knock-out in plant cells including
virus-induced gene silencing (VIGS) 361 12.11 Gene delivery in arthropod
and mammalian cells 362 12.12 Development of oncolytic virus and adaptation
to this purpose 363 12.13 Personal highlights and future directions 364
References 366 Index 375